Estel Grace Masangkay

Estel Grace Masangkay is a contributing writer for Life Science Connect who writes regular life sciences news features for several markets. She has a Bachelor’s degree from Gordon College.


  • Eli Lilly, Adocia To Co-Develop Ultra-Rapid Insulin

    Eli Lilly announced that it has entered into a global licensing partnership with clinical-stage biotech firm Adocia to co-develop an ultra-rapid insulin based on the latter’s proprietary technology as treatment for Type 1 and Type 2 diabetes.

  • Halozyme, Janssen Link To Develop Subcutaneous Drugs

    Halozyme Therapeutics announced that it has signed up with Janssen Biotech in a global collaboration to develop and market Janssen's subcutaneous treatments using the former's ENHANZE technology.

  • GSK Joins Consortium To Further Ebola Vaccine Development

    GlaxoSmithKline announced that it has joined an EU consortium with three other research institutions in order to further advance the development of GSK’s vaccine against the deadly virus Ebola.

  • TWi Biotech Gets U.S. And Taiwan Approval For AC-201 Phase 2 Trial

    TWi Pharmaceuticals announced that its subsidiary TWi Biotechnology has scored regulatory approvals from both U.S. and Taiwan authorities for the protocol of a Phase 2 clinical trial investigating its lead drug AC-201.

  • Abbott Wraps Up Acquisition Of Russian Firm Veropharm

    Abbott announced that it has completed its acquisition of leading Russian pharma manufacturer Veropharm.

  • GSK Files MAA For Volibris To Treat PAH In EU

    GlaxoSmithKline reported that it has filed a variation of Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for its drug Volibris (ambrisentan) to include pulmonary arterial hypertension (PAH) in its indication as a combination treatment.

  • Boston’s IND For Type 2 Diabetes Drug Accepted By FDA

    Boston Therapeutics announced that its Investigational New Drug Application (IND) for BTI-320 as treatment for Type 2 diabetes and to help manage weight has been accepted for review by the U.S. Food and Drug Administration (FDA).

  • La Jolla Licenses LJPC-501 To Washington University

    La Jolla Pharmaceuticals announced that it has entered into an exclusive global license agreement with the George Washington University concerning intellectual property rights of its drug LJPC-501 as a treatment for hypotension and shock.

  • Pfizer Signs Immunotherapy Deal With iTeos Therapeutics

    Belgian biotech firm iTeos Therapeutics announced that it has signed a strategic collaboration with Pfizer for the licensing of several pre-clinical compounds against cancer immunosuppression targets.

  • AstraZeneca’s Moventig For OIC Approved In The EU

    AstraZeneca announced that the European Commission has green-lighted its drug Moventig (naloxegol) as treatment for opioid-induced constipation (OIC) in adult patients who haven’t been successfully treated with laxatives in the EU.